Screener
SG&A at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The source filing: Castle Biosciences’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-031263
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| OPERATING EXPENSES | ||
| Cost of sales (exclusive of amortization of acquired intangible assets) | 20,533 | 16,383 |
| Research and development | 14,428 | 12,588 |
| Selling, general and administrative | 64,899 | 58,620 |
| Amortization of acquired intangible assets | 2,226 | 28,325 |
| Total operating expenses, net | 102,086 | 115,916 |
| Operating loss | (18,407) | (27,928) |
| Interest income | 2,545 | 3,099 |
Item 1. Financial Statements.
FAQ
- What is Castle Biosciences's SG&A?
- Castle Biosciences (CSTL) reported SG&A of $64.9M in Q1 2026.
- How has Castle Biosciences's SG&A changed year-over-year?
- Castle Biosciences's SG&A increased by 10.7% year-over-year, from $58.62M to $64.9M.
- What is the long-term trend for Castle Biosciences's SG&A?
- Over 4 years (2021 to 2025), Castle Biosciences's SG&A has grown at a 27.5% compound annual growth rate (CAGR), from $86.74M to $229.32M.
- What does SG&A mean?
- Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.
Ask your AI about Castle Biosciences's sg&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude